4 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
Follow trilaciclib: new trials by email Literature Review of trilaciclib trials Research Report on trilaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer Trilaciclib, Sacituzumab Govitecan-hziy - Triple Negative Breast Cancer | Phase 2 | Terminated | G1 Therapeutics, Inc. | 30 | 2021-12-08 | 2025-01-29 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab Trilaciclib, Gemcitabine, Cisplatin - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Terminated | G1 Therapeutics, Inc. | 92 | 2021-06-04 | 2025-09-08 |
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4) Trilaciclib, Placebo, Docetaxel - Metastatic Non-Small Cell Lung Cancer, NSCLC | Phase 2 | Terminated | G1 Therapeutics, Inc. | 10 | 2021-04-30 | 2023-04-14 |
| Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Trilaciclib, Gemcitabine, Carboplatin - Triple-Negative Breast Neoplasms, Breast Neoplasm | Phase 2 | Terminated | G1 Therapeutics, Inc. | 102 | 2017-02-02 | 2022-03-23 |
Neoplasm Metastasis (2) · Triple Negative Breast Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Lung Neoplasms (1) · Urinary Bladder Neoplasms (1)
United States (4) · Belgium (1) · Bulgaria (1) · Croatia (1) · France (1) · Georgia (1) · Hungary (1) · North Macedonia (1) · Serbia (1) · Slovakia (1) · Slovenia (1) · Spain (1)
2016 (1)